alendronate / Generic mfg. - LARVOL DELTA

Percutaneous Kyphoplasty combined with different anti-osteoporosis drugs for the treatment of osteoporotic vertebral compression fractures. (PubMed, Pak J Med Sci) - "The extent of vertebral loss in Group-C was significantly lower than Groups A and B (P<0.05). In the treatment of osteoporotic vertebral compression fractures after percutaneous kyphoplasty, a combination of calcium therapy with calcitonin and alendronate sodium had a positive effect, which may effectively improve bone density, pain, and functional status, and reduce the incidence of vertebral body fractures."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Pain • Rheumatology

EURODEC: Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study) (clinicaltrials.gov) - P=N/A | N=125 | Recruiting | Sponsor: 424 General Military Hospital | Trial completion date: Nov 2026 ➔ Nov 2027 | Trial primary completion date: Nov 2026 ➔ Nov 2027

Trial completion date • Trial primary completion date • Osteoporosis • Rheumatology

Retraction notice to "Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes" [Diabetes Res. Clin. Pr. 93 (2011) 166-173]. (PubMed, Diabetes Res Clin Pract) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Iodine-Induced Thyrotoxicosis Leading to Severe Osteoporosis: A Case Report (ENDO 2025) - "Common sources include iodized salt, amiodarone, and seaweed-based supplements such as kelp. We report a case of iodine-induced thyrotoxicosis secondary to kelp consumption, resulting in severe osteoporosis, emphasizing the importance of dietary awareness in thyroid management.CaseA 58-year-old woman with osteoporosis, low BMI, and premature ovarian insufficiency (POI) was evaluated for worsening bone density despite prior treatment with alendronate...She was advised to avoid excessive iodine and was treated with prednisone. She also started denosumab but was lost to follow-up...Comprehensive care should include dietary counseling and, when needed, psychiatric evaluation to address behavioral patterns contributing to excessive supplement use and related health risks.*. .*"

Case report • Clinical • Cardiovascular • Endocrine Disorders • Movement Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Psychiatry • Rheumatology • Women's Health

A Rare Case of Nail Patella Syndrome and Osteoporosis (ENDO 2025) - "Alendronate was prescribed from 2005 to 2012...Due to her low C-telopeptide and improvement in her DXA a bisphosphonate holiday was reinitiated in 2024.Clinical lessons: Patients with nail patella syndrome have a higher risk of early osteoporosis and should be monitored closely to evaluate for early intervention.*. .*"

Clinical • Allergic Rhinitis • Dermatology • Endocrine Disorders • Gastroesophageal Reflux Disease • Immunology • Inflammation • Musculoskeletal Diseases • Ophthalmology • Orthopedics • Osteoporosis • Pulmonary Disease • Renal Disease • Rheumatology • Urology

Exploring a Potential Link Between Romosozumab and Retinal Vein Occlusion: A Case Study (ENDO 2025) - "Further research is needed to clarify the vascular safety profile of romosozumab.References1) Asadipooya K, Weinstock A. Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate. 2017; 377(15):1417-1427*. .*"

Case study • Clinical • Age-related Macular Degeneration • Cardiovascular • Endocrine Disorders • Hematological Disorders • Hypertension • Macular Degeneration • Musculoskeletal Diseases • Musculoskeletal Pain • Myocardial Infarction • Ophthalmology • Orthopedics • Osteoporosis • Pain • Retinal Disorders • Retinal Vein Occlusion • Rheumatology • Thrombosis

Comparative Effects of Denosumab and Alendronate on Incidence of Type 2 Diabetes Mellitus in Patients with Osteoporosis: A Nationwide Study (ENDO 2025) - "Given the observational nature of the study and potential residual confounding factors, further prospective research with longer follow-up and detailed clinical data is warranted to clarify the long-term metabolic effects of antiosteoporotic agents.*. .*"

Clinical • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Renal Disease • Rheumatology • Type 2 Diabetes Mellitus

"Strengthening Bones, Supporting Lives: Romosozumab in Osteoporosis Management for Marfan Syndrome" (ENDO 2025) - "For osteoporosis, patient was previously on alendronate followed by raloxifene with a combined treatment course of approximately 15 years. This case report highlights this therapy as a possible effective therapeutic intervention but also recognizes the need for ongoing research to establish standard and effective treatment guidelines for management of osteoporosis in MFS.*. .*"

Endocrine Disorders • Genetic Disorders • Grave’s Disease • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • FBN1

Optimal Timing of Denosumab with Parathyroidectomy in the Setting of Primary Hyperparathyroidism​ (ENDO 2025) - "She started alendronate, calcium citrate, and high dose ergocalciferol prior to presenting to endocrinology...She remained on prednisone for 3 additional years while on denosumab... Parathyroidectomy was scheduled in proximity to the next denosumab dose since timing is important due to rebound resorption phenomenon and increased risk of vertebral fractures after delayed or missed denosumab doses. However, peri-procedural hypoparathyroidism and severe hypocalcemia can result if potent anti-resorptive therapy prevents liberation of calcium from bone. Considering this, denosumab was given 8 weeks after parathyroidectomy."

Cardiovascular • Dermatology • Endocrine Disorders • Grave’s Disease • Hypoparathyroidism • Immunology • Inflammatory Arthritis • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Psoriasis • Rheumatology • Secondary Hyperparathyroidism

Delayed Diagnosis of Hypophosphatasia in a 91-year-old: An Opportunity to Improve Screening (ENDO 2025) - "His low BMD had been treated with six 5-mg doses of zoledronate (ZOL) from 2010 to 2023 and alendronate prior to 2010...Additional ZOL was held and he was evaluated for asfotase alfa... HPP may be overlooked particularly in older adults with low BMD and low ALP on long-term bisphosphonate therapy as illustrated in this case. Our patient's low ALP level was presumed secondary to longstanding suppression of bone turnover from many years of bisphosphonate exposure. Although bisphosphonates can increase risk of atypical femur fractures in HPP, our patient had no such complications."

CNS Disorders • Depression • Musculoskeletal Diseases • Orthopedics • Otorhinolaryngology • Psychiatry • Rheumatology • ALPL

The Hidden Fallout of Childbirth: A Missed Sheehan's Syndrome Leading to Multiple Organ Dysfunction (ENDO 2025) - "Echocardiography revealed dilated cardiomyopathy (LVEF 30%), necessitating digoxin and diuretics...Endocrine replacement therapy was initiated with IV hydrocortisone, followed by oral prednisolone (5 mg and 2.5 mg) and thyroxine (50 to 100 mcg). Given her osteoporosis (DEXA T-score -3.0), alendronate, vitamin D, and calcium were added... Sheehan's syndrome can take years or decades to manifest, requiring a high index of suspicion in women with a history of agalactia, hypomenorrhea, or amenorrhea. Detailed obstetric history, attention to psychosomatic symptoms, and comprehensive endocrine evaluation, beyond TSH levels, are crucial for diagnosis. Women with a history of PPH should be closely monitored for hypopituitarism to prevent long-term complications.*."

Clinical • Anemia • Cardiomyopathy • Cardiovascular • Endocrine Disorders • Heart Failure • Hematological Disorders • Hypotension • Infectious Disease • Obstetrics • Osteoporosis • Pain • Postpartum Hemorrhage • Pulmonary Disease • Respiratory Diseases • Rheumatology • Severe Hypoglycemia • Tuberculosis • Women's Health

Significant One-Year Bone Mineral Density Gains Following a Single Dose of Romosozumab: Insights from Two Case Studies (ENDO 2025) - "Here we report the one-year bone mineral density (BMD) gains following one dose of Romosozumab in two anabolic-naive patients.Case PresentationPatient 1 is a 76-year-old female diagnosed with osteoporosis in August 2023 and treated with Alendronate 70 mg daily for four months, followed by one dose of Romosozumab in April 2024, with no subsequent treatment. Between August 2023 and September 2024, she had statistically significant improvements in BMD at the lumbar spine (13.9%), right femur (7.9%), and left femur (9.6%).Patient 2 is a 67 year old female with osteoporosis treated with one dose of Romosozumab in January 2024 followed by one dose of Zoledronic acid in February 2024...2.There is a need for further research to determine whether shorter treatment courses could reduce fractures effectively, minimize side effects, and lower the cost of osteoporosis care.*. .*"

Case study • Clinical • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

The Role of Full Femur Imaging for Early Detection of Incomplete Atypical Femur Fractures (ENDO 2025) - "Title: The Role of Full Femur Imaging for Early Detection of Incomplete Atypical Femur Fractures Introduction: Atypical femur fractures (AFFs) are a rare but serious complication linked to prolonged use of bisphosphonates and denosumab...After seven years on alendronate, she sustained a complete right AFF requiring intramedullary nailing...This case emphasizes the need for clear guidelines on screening for AFFs and the potential role of FFI in personalized imaging protocols to enhance patient care.*. .*"

Diabetes • Dyslipidemia • Endocrine Disorders • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • Type 2 Diabetes Mellitus

Challenges in Endocrine Function Testing During Clinical Cancer Drug Trials: False Positives Due to Heterophilic Antibodies (ENDO 2025) - "She was referred to the Endocrinology Department for osteoporosis management, and after evaluation, she was treated with Denosumab and cholecalciferol...Two months after switching to alendronate, PTH was measured at 1171 pg/mL...Following the initiation of osteoporosis treatment, the patient participated in a clinical trial to assess the safety and efficacy of Oregovomab in combination with Paclitaxel, Carboplatin, and Bevacizumab... Heterophilic antibodies have been recognized for a long time, but caution is needed as mouse-derived antibodies are still used in early-stage research. These antibodies can cross-react with non-homologous antigens, interfere with immunoassays, and lead to inaccurate test results.*. .*"

Clinical • Endocrine Disorders • Oncology • Osteoporosis • Ovarian Cancer • Pituitary Gland Carcinoma • Rheumatology • Solid Tumor

From Bone Density to Bone Death: Osteonecrosis of the Jaw in a Patient with Minimal Risk Factors (ENDO 2025) - "BRONJ occurs in 0.01%-0.06% of OP patients and up to 8% of cancer patients receiving higher and more frequent doses of antiresorptive medications or jaw radiation.Here we present a case of a 70-year-old female with a history of OP, who developed osteonecrosis of the jaw after 5 years of alendronate use with limited risk factors. Non-BP therapies, such as denosumab or teriparatide, could be considered to prevent further bone loss and fractures, but also carries the risk of ONJ, although data is limited.*. .*"

Clinical • Endocrine Disorders • Musculoskeletal Diseases • Oncology • Osteoporosis • Pain • Rheumatology

Effects of bisphosphonates & denosumab on bone mineral density in patients with osteoporosis - A study from central India. (ENDO 2025) - "Three groups of treatment alendronate- N=13, Zoledronic acid- N=39 & denosumab- N=11 allocated. Treating such patients had resulted rewarding results.*. .*"

Clinical • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Bisphosphonate Related Avascular Necrosis of the Humerus: A Case Report (ENDO 2025) - "At the February 2022 visit, patient was placed on oral alendronate 70 mg once weekly and was discharged to her PCP for monitoring... This case illustrates a rare but important complication of bisphosphonate therapy. Early recognition and discontinuation of bisphosphonates, followed by appropriate treatment such as teriparatide improves outcomes in affected patients. Further research is needed to better understand the mechanisms of bisphosphonates as the etiology of AVN and to identify patients at greatest risk for this complication."

Case report • Clinical • Cognitive Disorders • Dry Eye Disease • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Ophthalmology • Orthopedics • Osteoporosis • Pain • Rheumatology • Sjogren's Syndrome • Xerostomia

Exploring UV Spectroscopic Approaches for Alendronate Sodium Quantification in Pharmaceutical and Biological Samples. (PubMed, Crit Rev Anal Chem) - "This fluorescence quenching and restoration system has shown great potential in offering sensitive detection of alendronate. This review article discusses with the specific focus on UV-spectroscopic techniques which are not only economical and easy to operate but also crucial for monitoring the controlled release of the drug."

Journal • Review • Dental Disorders • Osteoporosis • Periodontitis • Rheumatology

Amino-bisphosphonates enhance CD8+ T cell responses to vaccine antigens by an ATRAID dependent mechanism (IMMUNOLOGY 2025) - "Here, we have examined the effect of alendronate (ALD), a nitrogen containing BP, on the response of CD8 + T cells to immunization with a model vaccine consisting of chicken ovalbumin (OVA) and CpG as an adjuvant...Moreover, ALD combination with OVA + CpG enhanced the response of adoptively transferred ATRAID sufficient OVA-specific OT-I CD8 T cells in WT recipients, but failed to do so in ATRAID -/- recipients. These data indicate that ALD is capable of enhancing the CD8+ T cell response to exogenous antigens by a mechanism that is critically dependent on the presence of ATRAID in one or more cell types other than CD8 T cells."

Infectious Disease • Osteoporosis • CD8 • GZMB • IFNG

Improving the effector function of Vd2+ ?d T cells through modulating platelet activity. (IMMUNOLOGY 2025) - "Human Vδ2+ T cells were expanded for 18 days with alendronate and subsequently cocultured with platelets at 1:20 and 1:50 ratios for 18 hours...Flow cytometric analysis revealed that the cytotoxic capacity of Vδ2+ T cells increased by over 20% in target cell killing in a manner that can be reversed by treating the cultures with platelet inhibitors. These findings suggest that platelets may enhance the cytotoxic potential of Vδ2+ T cells, underscoring a promising avenue for developing platelet-mediated immunotherapies."

IO biomarker

Safety profile and risk factors associated with incadronate disodium treatment in breast cancer patients with bone metastases: A retrospective analysis. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 5:00 PM EDT"

Retrospective data • Breast Cancer • Oncology • Solid Tumor

Bone mineral density and microarchitecture improvement in a young patient with Hajdu-Cheney syndrome and autosomal dominant polycystic kidney disease treated with alendronate. (PubMed, Bone Rep) - "This case highlights the effectiveness of alendronate in managing osteoporosis in a patient with HCS and ADPKD, despite the current lack of strong supportive evidence. Long-term monitoring revealed substantial improvements in bone density and microarchitecture, underscoring the importance of early diagnosis and intervention for genetic causes of osteoporosis to prevent fracture-related morbidity."

Journal • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Polycystic Kidney Disease • Renal Disease • Rheumatology • NOTCH2 • PKD1 • PRKD1

Chitosan-aloe vera scaffolds with tuned extracellular vesicles and histatin-5 display osteogenic and anti-biofilm activities. (PubMed, Int J Pharm) - "In this study, we stimulated mesenchymal stem cells (MSCs) with therapeutic agents affecting the bone regenerative cascade, including bone morphogenetic protein 2 (BMP-2), stromal-derived factor (SDF-1), interleukin 4 (IL-4), alendronate (ALD) and osteogenic differentiation media to obtain osteogenic EVs...This study demonstrates the successful combination of bioengineered EVs and Hist-5-loaded microspheres within a chitosan-AV scaffold, providing a promising dual approach for enhancing bone regeneration while reducing the risk of infection. These systems show potential as effective implants for bone fractures, offering both antibacterial and regenerative capabilities."

Journal • Infectious Disease • Musculoskeletal Diseases • Orthopedics • BMP2 • CXCL12 • IL4

Duplications within exon 1 of TNFRSF11A encoding receptor activator of nuclear factor-kappa B (RANK) are associated with tendon avulsion. (PubMed, Bone) - "Tendon avulsion seems to be a complication of constitutive RANK activation from select duplications of TNFRSF11A, but its precise pathogenesis and the impact of bisphosphonate therapy remain uncertain. Bisphosphonate therapy can treat or prevent associated immobilization hypercalcemia and decrease BTMs in people with constitutive RANK activation from such mutations."

Journal • Endocrine Disorders • Metabolic Disorders • Musculoskeletal Diseases • Oncology • Orthopedics • Otorhinolaryngology • Pain • TNFRSF11A

Minimizing STOPP and Beers Criteria Risks in PIM Treatments Using PM-TOM and ChatGPT: A Case Study. (PubMed, Stud Health Technol Inform) - "She was initially prescribed acetaminophen, alendronate, omeprazole, lisinopril, metoprolol, aspirin, citalopram, and vitamin D, which were assessed as inadequate...In the optimized treatment, omeprazole (PPI) was replaced with famotidine (H2-blocker), citalopram (SSRI) with agomelatine (atypical antidepressant), zoledronic acid (bisphosphonate) with denosumab (RANK ligand inhibitor), aspirin (NSAID) with ticagrelor (antiplatelet), and lisinopril with benazepril (ACE inhibitor)...Finally, ChatGPT validated the proposed adjustments, confirming their alignment with the guidelines and highlighting the potential for longer-term benefits. This case study illustrates how a combined use of PM-TOM and AI tools can effectively support the clinical decision-making process by optimizing polypharmacy treatments and minimizing their PIMs, major contributors to morbidity in older adults and high healthcare costs."

Journal • Cardiovascular • CNS Disorders • Coronary Artery Disease • Depression • Gastroesophageal Reflux Disease • Heart Failure • Hypertension • Immunology • Osteoarthritis • Osteoporosis • Pain • Psychiatry • Rheumatology